Simultaneous determination of salicylic acid and salicylamide in biological fluids

A new methodology for the simultaneous determination of salicylic acid and salicylamide in biological fluids is proposed. The strong overlapping of the fluorescence spectra of both analytes makes impossible the conventional fluorimetric determination. For that reason, the use of fluorescence decay curves to resolve mixtures of analytes is proposed; this is a novel technique that provides the benefits in selectivity and sensitivity of the fluorescence decay curves. In order to assess the goodness of the proposed method, a prediction set of synthetic samples were analyzed obtaining recuperation percentages between 98.2 and 104.6%. Finally, a study of the detection limits was done using a new criterion resulting in values for the detection limits of 8.2 and 11.6 μg L(-1) for salicylic acid and salicylamide respectively. The validity of the method was tested in human serum and human urine spiked with aliquots of the analytes. Recoveries obtained were 96.2 and 94.5% for salicylic acid and salicylamide respectively.

Simultaneous determination of salicylamide and salsalate in serum and urine by first derivative variable-angle synchronous fluorescence spectrometry

The determination of salicylamide and salsalate in human serum and urine is performed using a simple, rapid, sensitive, and selective method. The broad-band overlapping conventional spectra of both compounds are resolved by means of first derivative variable-angle synchronous fluorescence spectrometry. The method is based on the intrinsic fluorescence of both drugs in chloroformic solution. The measurements are performed in an alkaline medium, which is adjusted by adding 0.40 M pyrrolidine chloroformic solution to the organic phase. The method was applied for the simultaneous determination of salicylamide and salsalate, at concentrations between 0.100 and 1. 000 microg mL-1 for both components, by means of absolute values of a first derivative variable-angle synchronous scan at the emission/excitation wavelengths of 410/299 nm for salicylamide and 440/307 nm for salsalate. Serum and urine are extracted with chloroform, by adding acetate buffer solution to provide pH 4.8 in the aqueous phase. Finally, pyrrolidine chloroformic solution is added to organic phase, where both components are determined, without the need for a reextraction step to an aqueous phase.

High-performance liquid chromatographic method for the quantitation of salicylamide and its metabolites in biological fluids

A high-performance liquid chromatographic (HPLC) assay is described for the determination of salicylamide (SAM) and its metabolites in biological fluids obtained from an in situ rat liver preparation and rat in vivo. SAM and its six metabolites, salicylamide sulphate, salicylamide glucuronide, gentisamide (GAM), gentisamide 2-sulphate, gentisamide 5-sulphate and gentisamide 5-glucuronide, were separated on a mu Bondapak C18 column with 0.085 M potassium dihydrogenphosphate pH 3.35, as mobile phase and by using a flow gradient. Enriched recovery of SAM and GAM from blood was achieved by extraction followed by a second HPLC procedure with a mobile phase consisting of acetic acid and methanol. Furthermore, the reproducibility and the stability of the samples under assay conditions were investigated.

On-line low-level radiometric detection of [14C]remoxipride in liquid chromatographic effluents. Application to urine samples

A method for on-line radiometric detection in liquid chromatography (LC) is described that permits the detection of low levels of radioactivity in LC effluents by using solvent segmentation and storage of the segmented effluent in a capillary storage loop. The object of the method is to make the flow-rate in the on-line radioactivity monitor (and hence the mean residence time in the monitor) independent of the separation process. Therefore, after storage of the complete chromatogram, the segmented effluent is led through the monitor at flow-rates that can be chosen according to the residence time desired for accurate and precise radioactivity determination. In this system, it is possible to use a flow-cell volume small enough to preserve the chromatographic integrity, while maintaining the possibility of increasing the counting time. Tests have been performed on the reproducibility of 14C detection and the influence of the flow-rate through the monitor on the standard deviation in 14C peak area and, thus, on the detection limit, using 14C-labelled remoxipride. As an application, analyses of urine samples for [14C]remoxipride and one of its potential metabolites are reported.

Availability studies on acetylsalicylic acid, salicylamide and phenacetin at different pH values

The optimum partitioning rate of acetylsalicylic acid has been attained at pH = 4 and minimum partitioning rate was found to be at pH = 8. The maximum partitioning rate of salicylamide was observed at pH = 5 and the smallest one was found at pH = 6 or 8. At pH = 3 a maximum amount of phenacetin was found in the aqueous phase, while at pH = 6 a maximum amount was found in the octanolic layer. The maximum partitioning rate was found at pH = 6 and lowest one was observed at pH = 3. The gastrointestinal absorption of acetylsalicylic acid, salicylamide and phenacetin was significantly increased, as reflected by the urinary excretion data in presence of solid buffer components at pH values of 4,5 and 6 respectively.

Salicylamide-Glucuronide formation in children with favism and in their parents

Salicylamide-glucuronide formation has been determined in 27 children who underwent a favism crisis, 25 parents, and in 25 normal children who served as controls. A highly significant mean lower glucuronide formation was observed in the favism group in respect to the controls. The difference between fabic children and their parents was significant, and between parents and controls there was no significant difference.

Quantitative analysis of tribromsalan in blood and urine

Tribromsalan can be quantitatively measured in whole blood and urine by a technique involving extraction with ethyl acetate, treatment with silica gel, separation by TLC, and quantitative measurement by fluorescent spectrophotometry. This method has a sensitivity down to 125 ng (25 ppb in 5.0 ml of sample) of free tribromsalan and shows an average 90% recovery of tribromsalan in blood and urine with standard deviations of 9.7 and 7.4%, respectively.

The influence of pyrogen-induced fever on salicylamide metabolism in man

Salicylamide is metabolized in man by biotransformation to salicylamide glucuronide, salicylamide sulfate, and gentisamide glucuronide. The metabolites are quantitatively and rapidly excreted in urine. Study of the metabolism of this drug in volunteers during episodes of pyrogen-induced fever shows a significant reduction in the half-life (t(1/2)) of the excretion of the drug metabolites. The proportion of the drug transformed to its major metabolite, salicylamide glucuronide, is significantly reduced by fever, with concomitant increase in the proportion of one or both of the other metabolites. Thus, the pattern of urinary metabolites of salicylamide is altered. The shortened t(1/2) of the metabolite excretion is probably due to increased hepatic and renal blood flow known to accompany pyrogen-induced fever. This concept was supported by the observation that when two subjects were placed in a high-temperature environmental chamber, a condition in which hepatic and renal blood flows are known to diminish, the t(1/2) of salicylamide metabolite excretion actually increased. No simple explanation exists to explain the changed metabolite pattern noted during febrile periods. It is most likely to be due to complex interactions between the direct or indirect effects of the pyrogens and the factors affecting the hepatic biotransformation of drugs.